Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ACSS2
REST API REST API
Homo sapiens
ACSS2 is differentially expressed in 166 experiments: 71 organism parts: adipose tissue, bone marrow, ... (69 more);, 75 disease states: normal, breast carcinoma, ... (73 more);, 49 cell types 304 cell lines 22 compound treatments and 45 other conditions.
Synonyms ACS, AceCS, dJ1161H23.1, ACAS2, ACSA
Orthologs acss2 (Danio rerio)   Acss2 (Rattus norvegicus)   Acss2 (Mus musculus)   ACSS2 (Gallus gallus)   A7YWF1_BOVIN (Bos taurus)   ENSCING00000008830 (Ciona intestinalis)   ACS2 (Saccharomyces cerevisiae)   AcCoAS (Drosophila melanogaster)   ACS1 (Saccharomyces cerevisiae)   acss2.1 (Xenopus laevis)   ACSS2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, ligase activity, AMP binding, cytoplasm, metabolic process, lipid biosynthetic process, intracellular membrane-bounded organelle, ATP binding, nucleus, ethanol oxidation, nucleotide binding, catalytic activity, acetate-CoA ligase activity, xenobiotic metabolic process, acetyl-CoA biosynthetic process
InterPro Term AMP-dep_Synth/Lig, Ac_CoA_lig, Acyl-CoA_synth_DUF3448
UniProt Accession Q6DKJ3, Q96FY7, Q4G0E8, C9IYL0, Q9NR19, C9J7L5, Q5QPH3, B3KUV2, C9JXD9, C9JY31, B4DEH9, E7EWU3, F6WZD5, F8WDJ9, F8WCJ4, F8WBQ7, F8WC73, F8WB02, E1P5P8
Search EB-eye ENSG00000131069
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-803, E-GEOD-6573, E-GEOD-6919, E-TABM-130, ... (16 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-22152, E-GEOD-19639, E-GEOD-24147, E-GEOD-19480, ... (21 experiments)

Factor Value U/D Experiments
A549
2
E-GEOD-6013, E-GEOD-3202
MCF-7
2
E-GEOD-19639, E-GEOD-20081
SKNDZ
1
E-MTAB-37
NCIH69
1
E-MTAB-37
UMUC3
1
E-MTAB-37
SJRH30
1
E-MTAB-37
298 more value(s).


Cell type

studied in E-MEXP-1242, E-TABM-40, E-GEOD-20193, E-MEXP-1121, E-GEOD-21668, ... (27 experiments)

Factor Value U/D Experiments
not specified
2
E-GEOD-11755, E-GEOD-18811
iPS cells from episomal vectors (Defined Factor)
1
E-GEOD-20033
BDCA3+ dendritic cell
1
E-TABM-34
erythropoietic
1
E-GEOD-9894
CD14+ CD16- peripheral blood monocyte
1
E-MEXP-1242
CD8+ naive CD8 T cell
1
E-TABM-40
43 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-2508, E-GEOD-15960, E-MEXP-882, ... (31 experiments)

Factor Value U/D Experiments
papillary lung adenocarcinoma
1
E-MTAB-37
colorectal adenocarcinoma
1
E-AFMX-5
acute HIV-1 infection
1
E-GEOD-16363
squamous cell carcinoma
1
E-MTAB-37
FAB: M4 acute myeloid leukemia
1
E-GEOD-12662
Bmi1-shRNA
1
E-GEOD-21912
69 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5741, E-TABM-782, E-MEXP-1958, E-MEXP-2590, ... (13 experiments)

Factor Value U/D Experiments
poly(I:C)
1
E-MEXP-1230
TTA
1
E-MEXP-2590
unknown
1
E-GEOD-7307
mannitol
1
E-GEOD-6400
actinomycin D
1
E-GEOD-6400
HMB-PP (phosphoantigen)
1
E-MEXP-1601
16 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-4922

Factor Value U/D Experiments
78 years
1
E-GEOD-4922
78
1
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-21374, E-GEOD-20499, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743

Disease staging
studied in E-GEOD-19743, E-GEOD-22544

Environmental stress
studied in E-GEOD-1643

Estrogen receptor status
studied in E-GEOD-6532

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-MEXP-1235, E-TABM-868, E-MEXP-1648, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

Growth condition
studied in E-MEXP-2657, E-GEOD-21612, E-GEOD-20504, E-GEOD-19018, E-MEXP-1103, ... (7 experiments)

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-176, E-MEXP-1290, E-TABM-666, ... (14 experiments)

Infection
studied in E-GEOD-12108

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-1657, E-MEXP-1403

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-19246

RNAi
studied in E-MEXP-1857, E-MEXP-1315, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Test result
studied in E-GEOD-2748

Treatment
studied in E-GEOD-16837

Processing time: 0.313 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM